Antonio Avallone1, Luigi Aloj2, Biagio Pecori3, Corradina Caracò2, Alfonso De Stefano4, Fabiana Tatangelo5, Lucrezia Silvestro4, Vincenza Granata6, Francesco Bianco7, Carmela Romano4, Francesca Di Gennaro2, Alfredo Budillon8, Antonella Petrillo6, Paolo Muto3, Gerardo Botti5, Paolo Delrio7, Secondo Lastoria2. 1. Experimental Clinical Abdominal Oncology, IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale," Naples, Italy a.avallone@istitutotumori.na.it. 2. Nuclear Medicine, IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale," Naples, Italy. 3. Radiotherapy, IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale," Naples, Italy. 4. Experimental Clinical Abdominal Oncology, IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale," Naples, Italy. 5. Pathology, IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale," Naples, Italy. 6. Radiology, IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale," Naples, Italy. 7. Colorectal Oncological Surgery, IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale," Naples, Italy; and. 8. Experimental Pharmacology, IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale," Naples, Italy.
Abstract
There is an unmet need for predictive biomarkers of the clinical benefit of antiangiogenic drugs. The aim of the present study was to prospectively evaluate the value of 18F-FDG PET/CT performed during and after preoperative chemoradiotherapy with bevacizumab for the prediction of complete pathologic tumor regression and survival in patients with MRI-defined high-risk locally advanced rectal cancer. Methods: Sixty-one patients treated in a nonrandomized phase II study (BRANCH) with concomitant or sequential (4 d before chemoradiotherapy) administration of bevacizumab with preoperative chemoradiotherapy were included. 18F-FDG PET/CT was performed at baseline, 11 d after the beginning of chemoradiotherapy (early), and before surgery (late). Metabolic changes were compared with pathologic complete tumor regression (TRG1) versus incomplete tumor regression (TRG2-TRG5), progression-free survival, cancer-specific survival, and overall survival. Receiver-operating-characteristic curves were calculated for those 18F-FDG PET/CT parameters that significantly correlated with TRG1. Results: Early total-lesion glycolysis and its percentage change compared with baseline (ΔTLG-early) could discriminate TRG1 from TRG2-TRG5. Only receiver-operating-characteristic analysis of ΔTLG-early showed an area under the curve greater than 0.7 (0.76), with an optimal cutoff at 59.5% (80% sensitivity, 71.4% specificity), for identifying TRG1. Late metabolic assessment could not discriminate between the 2 groups. After a median follow-up of 98 mo (range, 77-132 mo), metabolic responders (ΔTLG-early ≥ 59.5%) demonstrated a significantly higher 10-y progression-free survival (89.3% vs. 63.6%, P = 0.02) and cancer-specific survival (92.9% vs. 72.6%, P = 0.04) than incomplete metabolic responders. Conclusion: Our results suggest that early metabolic response can act as a surrogate marker of the benefit of antiangiogenic therapy. The findings provide further support for the use of early 18F-FDG PET/CT evaluation to predict pathologic response and survival in the preoperative treatment of patients with locally advanced rectal cancer. ΔTLG-early showed the best accuracy in predicting tumor regression and may be particularly useful in guiding treatment-modifying decisions during preoperative chemoradiotherapy based on expected response.
There is an unmet need for predictive biomarkers of the clinical benefit of antiangiogenic drugs. The aim of the present study was to prospectively evaluate the value of 18F-FDG PET/CT performed during and after preoperative chemoradiotherapy with bevacizumab for the prediction of complete pathologic tumor regression and survival in patients with MRI-defined high-risk locally advanced rectal cancer. Methods: Sixty-one patients treated in a nonrandomized phase II study (BRANCH) with concomitant or sequential (4 d before chemoradiotherapy) administration of bevacizumab with preoperative chemoradiotherapy were included. 18F-FDG PET/CT was performed at baseline, 11 d after the beginning of chemoradiotherapy (early), and before surgery (late). Metabolic changes were compared with pathologic complete tumor regression (TRG1) versus incomplete tumor regression (TRG2-TRG5), progression-free survival, cancer-specific survival, and overall survival. Receiver-operating-characteristic curves were calculated for those 18F-FDG PET/CT parameters that significantly correlated with TRG1. Results: Early total-lesion glycolysis and its percentage change compared with baseline (ΔTLG-early) could discriminate TRG1 from TRG2-TRG5. Only receiver-operating-characteristic analysis of ΔTLG-early showed an area under the curve greater than 0.7 (0.76), with an optimal cutoff at 59.5% (80% sensitivity, 71.4% specificity), for identifying TRG1. Late metabolic assessment could not discriminate between the 2 groups. After a median follow-up of 98 mo (range, 77-132 mo), metabolic responders (ΔTLG-early ≥ 59.5%) demonstrated a significantly higher 10-y progression-free survival (89.3% vs. 63.6%, P = 0.02) and cancer-specific survival (92.9% vs. 72.6%, P = 0.04) than incomplete metabolic responders. Conclusion: Our results suggest that early metabolic response can act as a surrogate marker of the benefit of antiangiogenic therapy. The findings provide further support for the use of early 18F-FDG PET/CT evaluation to predict pathologic response and survival in the preoperative treatment of patients with locally advanced rectal cancer. ΔTLG-early showed the best accuracy in predicting tumor regression and may be particularly useful in guiding treatment-modifying decisions during preoperative chemoradiotherapy based on expected response.
Authors: Maarten Lambrecht; Christophe Deroose; Sarah Roels; Vincent Vandecaveye; Freddy Penninckx; Xavier Sagaert; Eric van Cutsem; Frederik de Keyzer; Karin Haustermans Journal: Acta Oncol Date: 2010-10 Impact factor: 4.089
Authors: Anne J Breugom; Marloes Swets; Jean-François Bosset; Laurence Collette; Aldo Sainato; Luca Cionini; Rob Glynne-Jones; Nicholas Counsell; Esther Bastiaannet; Colette B M van den Broek; Gerrit-Jan Liefers; Hein Putter; Cornelis J H van de Velde Journal: Lancet Oncol Date: 2015-01-12 Impact factor: 41.316
Authors: Lioe-Fee de Geus-Oei; Dennis Vriens; Hanneke W M van Laarhoven; Winette T A van der Graaf; Wim J G Oyen Journal: J Nucl Med Date: 2009-05 Impact factor: 10.057
Authors: Leonard L Gunderson; Daniel J Sargent; Joel E Tepper; Norman Wolmark; Michael J O'Connell; Mirsada Begovic; Cristine Allmer; Linda Colangelo; Steven R Smalley; Daniel G Haller; James A Martenson; Robert J Mayer; Tyvin A Rich; Jaffer A Ajani; John S MacDonald; Christopher G Willett; Richard M Goldberg Journal: J Clin Oncol Date: 2004-04-05 Impact factor: 44.544
Authors: Axel Grothey; Eric E Hedrick; Robert D Mass; Somnath Sarkar; Sam Suzuki; Ramesh K Ramanathan; Herbert I Hurwitz; Richard M Goldberg; Daniel J Sargent Journal: J Clin Oncol Date: 2008-01-10 Impact factor: 44.544
Authors: Antonella Petrillo; Roberta Fusco; Mario Petrillo; Vincenza Granata; Paolo Delrio; Francesco Bianco; Biagio Pecori; Gerardo Botti; Fabiana Tatangelo; Corradina Caracò; Luigi Aloj; Antonio Avallone; Secondo Lastoria Journal: Oncotarget Date: 2017-01-31